Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Compounding with Biotechnology Products, Part 1: General Considerations

Author(s):  Allen Loyd V Jr

Issue:  Sep/Oct 2022 - Volume 26, Number 5
View All Articles in Issue

Page(s):  385-395

Compounding with Biotechnology Products, Part 1: General Considerations Page 1
Compounding with Biotechnology Products, Part 1: General Considerations Page 2
Compounding with Biotechnology Products, Part 1: General Considerations Page 3
Compounding with Biotechnology Products, Part 1: General Considerations Page 4
Compounding with Biotechnology Products, Part 1: General Considerations Page 5
Compounding with Biotechnology Products, Part 1: General Considerations Page 6
Compounding with Biotechnology Products, Part 1: General Considerations Page 7
Compounding with Biotechnology Products, Part 1: General Considerations Page 8
Compounding with Biotechnology Products, Part 1: General Considerations Page 9
Compounding with Biotechnology Products, Part 1: General Considerations Page 10
Compounding with Biotechnology Products, Part 1: General Considerations Page 11

Download in electronic PDF format for $75

Abstract:  Biotechnology drugs involve any technique that uses living organisms in their production or modification. These biotechnology drugs are prepared using different techniques such as recombinant DNA technology monoclonal antibody technologies along with tissue cultures living cells and cell enzymes to make specific products. These new pharmaceuticals are utilized in the diagnosis treatment and prevention of disease but, because of the risk of clinically important and unusual and potentially harmful adverse effects produced, these agents require increased safety surveillance, and it is very important for pharmacists to participate in any adverse event reporting and monitoring program for these new products. The first biotechnology pharmaceuticals are proteins, but, eventually, an ever-increasing number of smaller molecules may be discovered through the previously mentioned methods and may become a mainstay in new pharmaceutical research and development in producing new drug products. Pharmacists involved in compounding must be aware of not only the biotechnology agent itself but especially of all of the different excipients that are required in order to produce a stable and safe preparation for patient use. Compounding involving these formulations should involve the simplest procedures and formulations as possible, maintaining sterility throughout the entire process. It is important to maintain a drug’s biologic activity up to the point of administration to the patient, and the pharmacist can assist in explaining the various factors involved in storage preparation and administration of the drugs to the patient. In the next issue of this two-part series, we will look at the formulations for a number of commercially available biotechnology products and the purpose of each of the ingredients and any uniqueness about their formulations.

Related Keywords: Loyd V. Allen Jr., PhD, RPh, biotechnology drugs, recombinant DNA technology, monoclonal antibody technology, tissue cultures, living cells, cell enzymes, adverse events, drug safety, biosimilars, follow-on biologics, biologic agents, polymerase chain reaction, PCR, gene therapy, nucleotide blockage, antisense nucleic acids, rDNA, protein drugs, stabilizers, filter loss, container sorption, protein structure, isoelectric point, molecular weight, solubility, stability, quality control, agitation, tissue penetration, absorption, immune reaction, drug delivery, nanoparticles, liposomes, targeted delivery, polymer-drug conjugates, pegylation, polyethylene glycol, encapsulation, nanomedicine, diagnostic products, patient education, chelating agents, antioxidants, preservatives, tonicity

Related Categories: STABILITIES, COMPATIBILITIES, TECHNOLOGY, QUALITY CONTROL, PATIENT EDUCATION, ADVERSE DRUG EVENTS, PROFESSIONAL ISSUES

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Compounding with Biotechnology Products, Part 1: General Considerations
Allen Loyd V Jr
Sep/Oct 2022
Pg. 385-395

Compounding with Biotechnology Products, Part 2: Product-specific Considerations
Allen Loyd V Jr
Nov/Dec 2022
Pg. 446-466

Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh
Allen Loyd V Jr
Nov/Dec 2003
Pg. 449-450

Biotechnology, Nanotechnology, and Pharmacogenomics and Pharmaceutical Compounding, Part 2
Allen Loyd V
Jul/Aug 2015
Pg. 280-287

Biotechnology, Nanotechnology, and Pharmacogenomics and Pharmaceutical Compounding, Part 1
Allen Loyd V Jr
Jan/Feb 2015
Pg. 38-40

Safety Standards in Pharmaceutical Compounding, Part 3: Fire Safety
Allen W Chris
, Greeson Nicole MH, Mixon William
Nov/Dec 2020
Pg. 451-458

Basics of Compounding: Considerations for Implementing USP Chapter <797> Pharmacy Compounding -- Sterile Preparations, Part 20: Patient or Caregiver Training, Patient Monitoring and Adverse Events Reporting, and Quality-Assurance Program
Okeke Claudia C
, Allen Loyd V Jr
Jul/Aug 2010
Pg. 328-331

Basics of Compounding for Hazardous Drugs, Part 2: Regulation and Sources of Contamination
Allen Loyd V Jr
Nov/Dec 2006
Pg. 446-448

PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
Sep/Oct 2017
Pg. 356

Extemporaneous Topical Minoxidil Solutions for the Treatment of Alopecia: Stability Studies and Incorporation Tests of Active Ingredients in ALOPLUS FAST Base
Spennacchio Antonio
, Lopedota Angela Assunta, Lopalco Antonio, Dibenedetto Maria Teresa, la Forgia Flavia Maria, Fontana Sergio, Franco Massimo, Denora Nunzio
May/Jun 2023
Pg. 256-262

Sterile Compounding with Barrier-Isolation Technology
Rahe Hank
Jul/Aug 2001
Pg. 254-258

The Role of Compounding in Closing Therapeutic Gaps--Abstracts from FIP 2013
Lutz Eugene
, Pauletti Giovanni, Carvalho Maria, Davidson Gigi, Ashworth Lisa, Subramaniam Vaiyapuri, Llambí Francesc
Jan/Feb 2014
Pg. 6-12

Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A
Blankenship Cynthia E
Sep/Oct 2014
Pg. 379-380

Sterile Basics: Intravenous Admixture Compounding, Part 1: Introduction and Overview of the General Guidelines for an Intravenous Admixture Compounding Program, and Compounding Personnel Considerations
Allen Loyd V Jr
Mar/Apr 2023
Pg. 123-139

Nonsterile Basics of Compounding: Using U.S. Food and Drug Administration-approved Commercial Products as Ingredients
Allen Loyd V Jr
Nov/Dec 2023
Pg. 474-481

Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs
Dillon L R
Jan/Feb 2020
Pg. 30-36

Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials
Mueller Claudia
, Dietel Elde, Heynen Severin R, Nalenz Heiko, Goldbach Pierre, Mahler Hanns-Christian, Schmidt Johannes, Grauschopf Ulla, Schoenhammer Karin
May/Jun 2015
Pg. 261-267

Intravenous Admixture Preparation Considerations, Part 2: Incompatibilities and Factors Involved
Allen Loyd V Jr
Jan/Feb 2020
Pg. 44-50

Single Center Experience with Robot Technologies for Sterile Compounding: A Retrospective Review
Milibari Loay
, Cotugno Michael, Belisle Caryn, Rocchio Megan, Patterson Robert F, Chacon Pablo, Fanikos John, Vo Peter
Jul/Aug 2020
Pg. 346-351

Intravenous Admixture Preparation Considerations, Part 9-A: Error Prevention in Intravenous Admixture Preparation
Allen Loyd V Jr
Mar/Apr 2021
Pg. 131-139

Return to Top